AstraZeneca, Sanofi infant respiratory treatment gets US approval
AstraZeneca and Sanofi's Beyfortus drug has been approved in the US for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants, the two companies said on Tuesday.
AstraZeneca
10,422.00p
17:15 23/12/24
1.62%
166.00p
CAC 40
7,274.48
17:00 23/12/24
0.00%
0.00
DJ EURO STOXX 50
4,862.28
00:00 21/12/24
-0.34%
-16.72
FTSE 100
8,102.72
17:14 23/12/24
n/a
n/a
FTSE 350
4,471.06
17:09 23/12/24
n/a
n/a
FTSE All-Share
4,428.73
16:44 23/12/24
n/a
n/a
Pharmaceuticals & Biotechnology
20,005.17
17:09 23/12/24
1.24%
244.05
Sanofi
€91.78
16:40 23/12/24
0.55%
€0.50
The treatment is given to those born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. Beyfortus will be available in the US ahead of the upcoming 2023-2024 RSV season, they added.